Seres Therapeutics Stock Discussion

$Seres Therapeutics (MCRB.US)$ Item 5 - Approval of amendments to the Company’s Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”) to effect a reverse stock split.
 
Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes.     85,742,623.            29,461,090                  187,192.                             0

$Seres Therapeutics (MCRB.US)$ going down to 55

$Seres Therapeutics (MCRB.US)$ Reuters· just
Seres Therapeutics Inc - Ser-155 Receives Breakthrough Therapy and Fast Track Designations

$Seres Therapeutics (MCRB.US)$ bear or bullish?

$Seres Therapeutics (MCRB.US)$ Press Release: Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
Dow Jones· 3 mins ago

$Seres Therapeutics (MCRB.US)$
Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows

$Seres Therapeutics (MCRB.US)$
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
Thursday, 9th January at 7:00 am
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of Seres' live ...

$Seres Therapeutics (MCRB.US)$ may this fly later. (:

$Seres Therapeutics (MCRB.US)$ Reuters· 3 mins ago
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)

$Seres Therapeutics (MCRB.US)$
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo
Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025
Ser...